Faron Pharmaceuticals Oy (LON:FARN)‘s stock had its “buy” rating reaffirmed by investment analysts at Panmure Gordon in a research note issued to investors on Monday, May 8th. They presently have a GBX 663 ($8.56) price objective on the stock. Panmure Gordon’s price target suggests a potential downside of 14.45% from the company’s previous close.
Faron Pharmaceuticals Oy (LON:FARN) opened at 775.00 on Monday. The company’s market capitalization is GBX 203.91 million. The company has a 50-day moving average price of GBX 677.36 and a 200 day moving average price of GBX 409.94. Faron Pharmaceuticals Oy has a 52-week low of GBX 240.75 and a 52-week high of GBX 825.00.
COPYRIGHT VIOLATION NOTICE: This piece of content was first published by Transcript Daily and is the property of of Transcript Daily. If you are viewing this piece of content on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this piece of content can be viewed at https://transcriptdaily.com/2017/05/20/panmure-gordon-reiterates-buy-rating-for-faron-pharmaceuticals-oy-farn-updated.html.
In other Faron Pharmaceuticals Oy news, insider Jonathan Knowles bought 1,000 shares of the company’s stock in a transaction on Tuesday, April 25th. The stock was purchased at an average cost of GBX 635 ($8.20) per share, for a total transaction of £6,350 ($8,196.72).
Faron Pharmaceuticals Oy Company Profile
Receive News & Ratings for Faron Pharmaceuticals Oy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Faron Pharmaceuticals Oy and related companies with MarketBeat.com's FREE daily email newsletter.